The U.S. Food and Drug Administration has approved Virbac Animal Health Inc.’s Easotic (hydrocortisone aceponate, miconazole nitrate, gentamicin sulfate) Suspension for the treatment of otitis externa in dogs.
The FDA approved the drug for the treatment of otitis externa in dogs associated with susceptible strains of yeast (Malassezia pachydermatis) and bacteria (Staphylococcus pseudintermedius). Administration of Easotic includes instilling 1 mL of the drug in the affected ear once daily for five days. Each milliliter contains 1.11 mg of hydrocortisone aceponate, 15.1 mg of miconazole nitrate, and 1,505 micrograms of gentamicin sulfate.
Virbac, based in Fort Worth, Texas, launched Easotic in Europe in 2009, where it is sold in an airless pump bottle.